{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T08:48:38Z","timestamp":1782031718236,"version":"3.54.5"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007210","name":"Varian Medical Systems Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007210","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Danish Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ijrobp.2025.07.1419","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T15:08:12Z","timestamp":1753369692000},"page":"320-329","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Stereotactic Ablative Radiation Therapy of Bone Metastases in an Oligometastatic Setting: One-Year Follow-Up of the BONY-M Phase 2 Trial"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5176-7701","authenticated-orcid":false,"given":"Nicklas Juel","family":"Spindler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette van Overeem","family":"Felter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olfred","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tine Bj\u00f8rn","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten Hiul","family":"Suppli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjana","family":"Josipovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurids \u00d8stergaard","family":"Poulsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Rahma-Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hella Maria Br\u00f8gger","family":"Sand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana Mikhailovna","family":"Abramova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefine Staahl","family":"Kornerup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam Delange","family":"Alsaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikke L\u00f8vendahl","family":"Eefsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Serup-Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Brun","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poul","family":"Geertsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan Richter","family":"Vogelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus Preibisch","family":"Behrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3363-3256","authenticated-orcid":false,"given":"Gitte Fredberg","family":"Persson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.07.1419_bib0001","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ijrobp.2022.05.004","article-title":"Stereotactic radiation for the comprehensive treatment of oligometastases (SABR-COMET): Extended long-term outcomes","volume":"114","author":"Harrow","year":"2022","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.07.1419_bib0002","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: The ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2025.07.1419_bib0003","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/jamaoncol.2020.6146","article-title":"Safety and survival rates associated with ablative stereotactic radiotherapy for patients with oligometastatic cancer: A systematic review and meta-analysis","volume":"7","author":"Lehrer","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2025.07.1419_bib0004","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.radonc.2018.03.030","article-title":"Local control and fracture risk following stereotactic body radiation therapy for non-spine bone metastases","volume":"127","author":"Erler","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.07.1419_bib0005","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ijrobp.2022.05.033","article-title":"Progression-free survival and local control after SABR for up to 5 oligometastases: An analysis from the population-based phase 2 SABR-5 trial","volume":"114","author":"Baker","year":"2022","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.07.1419_bib0006","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ijrobp.2022.05.043","article-title":"Mature local control and reirradiation rates comparing spine stereotactic body radiation therapy with conventional palliative external beam radiation therapy","volume":"114","author":"Zeng","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.07.1419_bib0007","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jamaoncol.2019.0192","article-title":"Single-fraction stereotactic vs conventional multifraction radiotherapy for pain relief in patients with predominantly nonspine bone metastases: A randomized phase 2 component of a phase 2\/3 trial","volume":"5","author":"Nguyen","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2025.07.1419_bib0008","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1200\/JCO.2013.50.1411","article-title":"Vertebral compression fracture after spine stereotactic body radiotherapy: A multi-institutional analysis with a focus on radiation dose and the spinal instability neoplastic score","volume":"31","author":"Sahgal","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.07.1419_bib0009","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.1016\/S1470-2045(13)70101-3","article-title":"Vertebral compression fracture after stereotactic body radiotherapy for spinal metastases","volume":"14","author":"Sahgal","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.07.1419_bib0010","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.ijrobp.2023.12.051","article-title":"Clinical outcomes following stereotactic body radiation therapy (SBRT) for non-spinal bone metastases: A systematic review and meta-analysis","volume":"119","author":"Singh","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.07.1419_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109576","article-title":"Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? A secondary analysis of the population-based phase II SABR-5 trial","volume":"182","author":"Eufemon Cereno","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.07.1419_bib0012","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.ijrobp.2022.01.002","article-title":"Determining planning priorities for SABR for oligometastatic disease: A secondary analysis of the SABR-COMET phase II randomized trial","volume":"114","author":"Van Oirschot","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.07.1419_bib0013","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document","volume":"148","author":"Lievens","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.07.1419_bib0014","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3171\/2010.3.SPINE09459","article-title":"Reliability analysis of the epidural spinal cord compression scale","volume":"13","author":"Bilsky","year":"2010","journal-title":"J Neurosurg Spine"},{"key":"10.1016\/j.ijrobp.2025.07.1419_bib0015","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.clon.2017.09.007","article-title":"UK consensus on normal tissue dose constraints for stereotactic radiotherapy","volume":"30","author":"Hanna","year":"2018","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ijrobp.2025.07.1419_bib0016","doi-asserted-by":"crossref","first-page":"861","DOI":"10.3109\/02841869509127197","article-title":"Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator: Clinical experience of the first thirty-one patients","volume":"34","author":"Blomgren","year":"1995","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ijrobp.2025.07.1419_bib0017","doi-asserted-by":"crossref","first-page":"e597","DOI":"10.1016\/j.ijrobp.2012.03.009","article-title":"International Spine Radiosurgery Consortium consensus guidelines for target volume definition in spinal stereotactic radiosurgery","volume":"83","author":"Cox","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.07.1419_bib0018","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.radonc.2019.11.026","article-title":"International consensus recommendations for target volume delineation specific to sacral metastases and spinal stereotactic body radiation therapy (SBRT)","volume":"145","author":"Dunne","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.07.1419_bib0019","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/sj.bjc.6605546","article-title":"Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer","volume":"102","author":"Hamaoka","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2025.07.1419_bib0020","doi-asserted-by":"crossref","first-page":"80","DOI":"10.7150\/jca.1.80","article-title":"Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST","volume":"1","author":"Costelloe","year":"2010","journal-title":"J Cancer"},{"key":"10.1016\/j.ijrobp.2025.07.1419_bib0021","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdu519","article-title":"Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: Comparison of skeletal-related events and symptomatic skeletal events","volume":"26","author":"Smith","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2025.07.1419_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: Building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.ijrobp.2025.07.1419_bib0023","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ijrobp.2022.11.035","article-title":"Using and understanding survival statistics - or how we learned to stop worrying and love the Kaplan-Meier estimate","volume":"115","author":"Bentzen","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.07.1419_bib0024","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ijrobp.2025.07.1419_bib0025","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ijrobp.2025.07.1419_bib0026","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"key":"10.1016\/j.ijrobp.2025.07.1419_bib0027","unstructured":"R Core Team and others. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Accessed May 24, 2023. http:\/\/www.R-project.org\/."},{"key":"10.1016\/j.ijrobp.2025.07.1419_bib0028","doi-asserted-by":"crossref","first-page":"e595","DOI":"10.1016\/S1470-2045(15)00166-7","article-title":"Response assessment after stereotactic body radiotherapy for spinal metastasis: a report from the SPIne response assessment in Neuro-Oncology (SPINO) group","volume":"16","author":"Thibault","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ijrobp.2025.07.1419_bib0029","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3174\/ajnr.A4528","article-title":"Osseous pseudoprogression in vertebral bodies treated with stereotactic radiosurgery: A secondary analysis of prospective phase I\/II clinical trials","volume":"37","author":"Amini","year":"2016","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.ijrobp.2025.07.1419_bib0030","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.ijrobp.2024.01.008","article-title":"Upfront versus delayed systemic therapy in patients with oligometastatic cancer treated with stereotactic ablative radiotherapy on the phase II SABR-5 trial","volume":"118","author":"Baker","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.07.1419_bib0031","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): A randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.ijrobp.2025.07.1419_bib0032","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13014-018-1040-z","article-title":"The alfa and beta of tumours: A review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies","volume":"13","author":"van Leeuwen","year":"2018","journal-title":"Radiat Oncol Lond Engl"},{"key":"10.1016\/j.ijrobp.2025.07.1419_bib0033","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.radonc.2022.05.035","article-title":"Deviation from consensus contouring guidelines predicts inferior local control after spine stereotactic body radiotherapy","volume":"173","author":"Chen","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.07.1419_bib0034","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.radonc.2022.05.024","article-title":"ESTRO ACROP guidelines for external beam radiotherapy of patients with uncomplicated bone metastases","volume":"173","author":"van der Velden","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.07.1419_bib0035","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1001\/jamaoncol.2023.0356","article-title":"Stereotactic radiosurgery vs conventional radiotherapy for localized vertebral metastases of the spine: Phase 3 results of NRG oncology\/RTOG 0631 randomized clinical trial","volume":"9","author":"Ryu","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2025.07.1419_bib0036","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: Long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.07.1419_bib0037","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: A prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.07.1419_bib0038","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.radonc.2018.04.030","article-title":"Randomized phase II trial evaluating pain response in patients with spinal metastases following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy","volume":"128","author":"Sprave","year":"2018","journal-title":"Radiother Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625060237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625060237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T08:32:29Z","timestamp":1782030749000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301625060237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0360301625060237"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.07.1419","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic Ablative Radiation Therapy of Bone Metastases in an Oligometastatic Setting: One-Year Follow-Up of the BONY-M Phase 2 Trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.07.1419","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}